Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic
31 janv. 2024 09h15 HE
|
Orgenesis Inc.
GERMANTOWN, Md., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralizing cell and gene therapies (CGTs), today announced it...
Orgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TM
14 nov. 2023 08h30 HE
|
Orgenesis Inc.
GERMANTOWN, Md., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Provides Business Update for the Third Quarter of 2023
13 nov. 2023 16h15 HE
|
Orgenesis Inc.
GERMANTOWN, Md., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Inc. Announces Pricing of $1.1 Million Registered Direct Offering
08 nov. 2023 09h00 HE
|
Orgenesis Inc.
GERMANTOWN, Md., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (“Orgenesis”) (Nasdaq: ORGS), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs),...
Orgenesis Announces Expanded Partnership Between Octomera and UC Davis Through CIRM Grant Funding
02 nov. 2023 08h00 HE
|
Orgenesis Inc.
GERMANTOWN, Md., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Announces Withdrawal of Proposed Public Offering
30 oct. 2023 21h30 HE
|
Orgenesis Inc.
GERMANTOWN, Md., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Announces Proposed Underwritten Public Offering
30 oct. 2023 16h07 HE
|
Orgenesis Inc.
GERMANTOWN, Md., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
CGT Global and Octomera Enter Agreement to Expand Cell & Gene Therapy Development and Patient Access Across the United States
21 sept. 2023 08h00 HE
|
Orgenesis Inc.
GERMANTOWN, Maryland, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Cell and Gene Therapy Industry Pioneer & GMP Expert, Gerhard Bauer, Joins Orgenesis Business, Octomera, to Drive Continued Expansion of POCare Facilities and Service Support
06 sept. 2023 07h00 HE
|
Orgenesis Inc.
GERMANTOWN, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Orgenesis, a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), continues to grow the infrastructure...
Orgenesis Provides Business Update for Second Quarter of 2023
11 août 2023 07h00 HE
|
Orgenesis Inc.
Reports Progress in Advancing the Rollout of the POCare Platform and POCare Therapeutic Pipeline Orgenesis to Host Conference Call Today at 8:00 AM ET GERMANTOWN, Md., Aug. 11,...